Cholecystokinin receptor antagonist, loxiglumide, inhibits invasiveness of human pancreatic cancer cell lines.
Recently, cholecystokinin has been reported to be important in regulating the growth of pancreatic cancer. We investigated the effect of loxiglumide (LXG), a cholecystokinin receptor antagonist, on the invasiveness of two human pancreatic cancer cell lines. Cells were treated with LXG for 24 h, and examined in the invasion assay. The expression and activity of MMP-9 in supernatants from cancer cells were analyzed by Western blotting and zymogram. Interestingly, the invasiveness of cancer cells and expression of MMP-9 were decreased by LXG in a dose-dependent manner. LXG may be a useful therapeutic agent against pancreatic cancer.
Hirata
M
M
First Department of Internal Medicine, Hiroshima University School of Medicine, Japan.
Itoh
M
M
Tsuchida
A
A
Ooishi
H
H
Hanada
K
K
Kajiyama
G
G
D015153:Blotting, Western; D002460:Cell Line; D017364:Collagenases / Q000032:analysis / Q000096:biosynthesis* / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004591:Electrophoresis, Polyacrylamide Gel; D005780:Gelatin; D006727:Hormone Antagonists / Q000494:pharmacology*; D006801:Humans; D007700:Kinetics; D020780:Matrix Metalloproteinase 9; D009361:Neoplasm Invasiveness; D010190:Pancreatic Neoplasms / Q000473:pathology*; D011377:Proglumide / Q000031:analogs & derivatives* / Q000494:pharmacology; D012844:Sincalide / Q000494:pharmacology; D014407:Tumor Cells, Cultured
D006727:Hormone Antagonists; C053737:loxiglumide; D005780:Gelatin; D017364:Collagenases; D020780:Matrix Metalloproteinase 9; D011377:Proglumide; D012844:Sincalide